Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.

Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian MarketSHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On ...

Related Keywords

China ,Philippines ,Shenzhen ,Guangdong , ,Pharmawealth Inc ,Human Health ,World Health Organization ,Shenzhen Kangtai Biological Products Co ,Minhai Biotechnology Co Ltd ,First Entry ,Pneumococcal Vaccine ,Southeast Asian ,Beijing Minhai ,Shenzhen Kangtai Biological Products ,Deadliest Superbugs ,Threaten Human ,Kangtai Biological Products ,